References
Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2018;68:7. https://doi.org/10.1038/s41571-018-0112-1.
Pilgrim CHC, Tsai S, Evans DB, Christians KK. Mesocaval shunting: a novel technique to facilitate venous resection and reconstruction and enhance exposure of the superior mesenteric and celiac arteries during pancreaticoduodenectomy. J Am Coll Surg. 2013;217:e17–20. https://doi.org/10.1016/j.jamcollsurg.2013.05.018.
Christians KK, Riggle K, Keim R, et al. Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: initial experience from the Medical College of Wisconsin. Surgery. 2013;154:123–31. https://doi.org/10.1016/j.surg.2012.11.019.
Simoneau E, Goumard C, Lee, JE, et al. Pancreaticoduodenectomy with mesocaval shunt for locally advanced pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26:652. https://doi.org/10.1245/s10434-018-07093-x.
Katz MHG, Fleming JB, Pisters PWT, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248:1098–102. https://doi.org/10.1097/sla.0b013e31818730f0.
Tran Cao HS, Balachandran A, Wang H, et al. Radiographic tumor–vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2013;18:269–78. https://doi.org/10.1007/s11605-013-2374-3.
Snyder RA, Prakash LR, Nogueras-Gonzalez GM, et al. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: patency rates and outcomes associated with thrombosis. J Surg Oncol. 2018;117:1648–54. https://doi.org/10.1002/jso.25067.
Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14:919–29. https://doi.org/10.1586/14737140.2014.919860.
Katz MHG, Lee JE, Pisters PWT, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012;215:e11–8. https://doi.org/10.1016/j.jamcollsurg.2012.05.015.
Tzeng C-WD, Balachandran A, Ahmad M, et al. (2014) Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB 16:430–8. 10.1111/hpb.12154.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
ASO Author Reflections offer a brief invited commentary on the article, “Pancreaticoduodenectomy With Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma”. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-018-07093-x
Rights and permissions
About this article
Cite this article
Simoneau, E., Katz, M.H., Lee, J.E. et al. ASO Author Reflections: Temporary Mesocaval Shunt: Indications and Technique for Safe Resection of Pancreatic Tumors With Mesenteric Venous Occlusion. Ann Surg Oncol 26 (Suppl 3), 579–580 (2019). https://doi.org/10.1245/s10434-019-07290-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-07290-2